Hermetica Superfood Encyclopedia
The Short Answer
Bloodroot contains quaternary benzophenanthridine alkaloids—primarily sanguinarine (up to 0.55% of fresh rhizome weight) and chelerythrine—that exert antimicrobial, antiproliferative, and immunomodulatory effects through DNA intercalation, enzyme inhibition, and cytokine modulation. In vitro studies demonstrate minimum inhibitory concentrations of 12.5–50.0 µg/ml against 15 strains of Helicobacter pylori and selective inhibition of K562 leukemia cell proliferation, though no human clinical trials have confirmed these effects in vivo.
CategoryRoot
GroupEuropean
Evidence LevelPreliminary
Primary Keywordbloodroot benefits
Bloodroot — botanical close-up
Health Benefits
**Antimicrobial Activity**
Sanguinarine and chelerythrine exhibit broad-spectrum antimicrobial properties with MICs of 12.5–62.5 µg/ml against H. pylori, E. coli, and other pathogens in vitro, supporting the traditional use of bloodroot for infections.
**Antiproliferative Effects**
Rhizome ethanol extracts strongly inhibit K562 leukemia cell proliferation in vitro, an effect correlated with sanguinarine and chelerythrine concentrations, suggesting potential relevance to oncology research.
**Immunomodulation**
Alkaloid fractions augment peripheral blood mononuclear cell (PBMC) proliferation and upregulate IFN-γ and IL-2 production while suppressing IL-4 and IL-10, shifting immune responses toward Th1-mediated cytotoxic activity.
**Anti-inflammatory Action**
Sanguinarine inhibits neutrophil chemotaxis, oxidative burst, and degranulation at concentrations as low as 0.001%, potentially reducing inflammatory tissue damage in conditions driven by excessive neutrophil activation.
**Expectorant and Respiratory Support**
Traditional use as an expectorant for bronchitis and upper respiratory congestion is supported by its alkaloid-driven mucosal secretion effects, though clinical trial data in humans are absent.
**Anti-platelet and Anti-angiogenic Properties**
Sanguinarine inhibits platelet aggregation and demonstrates anti-angiogenic activity in preclinical models, suggesting cardiovascular and tumor microenvironment relevance pending further study.
**Escharotic/Topical Antimicrobial Use**
Historically applied as an escharotic agent for skin lesions, with in vitro antimicrobial support; however, topical use for skin cancer lacks clinical evidence and carries significant safety concerns.
Origin & History
Natural habitat
Bloodroot is a perennial herbaceous plant native to eastern North America, ranging from Nova Scotia south to Florida and west to the Great Plains, thriving in rich, moist deciduous woodland soils with partial shade. It grows from a thick, horizontal rhizome that exudes a distinctive red-orange sap when cut, from which both its common name and genus name Sanguinaria (from Latin sanguis, blood) derive. Historically cultivated and wildcrafted by Indigenous peoples across its native range, the plant flowers briefly in early spring before the foliage expands, with rhizomes harvested mid-spring at peak alkaloid content for medicinal preparations.
“Bloodroot holds a prominent place in Native American ethnobotany, used by the Algonquin, Cherokee, Iroquois, and numerous other Indigenous nations as a topical antimicrobial, escharotic agent for skin growths, treatment for respiratory infections, and as a ceremonial body paint owing to its vivid red sap. European settlers adopted these uses in Appalachian folk medicine, incorporating dried rhizome preparations into expectorant formulas for bronchitis and croup, a practice documented in early American pharmacopeias and Eclectic medical texts of the 18th and 19th centuries. The 19th-century Eclectic physicians listed Sanguinaria canadensis in their materia medica specifically for chronic bronchitis, laryngitis, and nasal polyps, typically prescribing tincture doses far below emetic thresholds. In more recent decades, bloodroot gained controversial attention as a component of 'black salve' escharotic preparations marketed for skin cancer, uses that lack clinical validation and have been associated with serious tissue disfigurement.”Traditional Medicine
Scientific Research
The evidence base for bloodroot consists exclusively of in vitro and preclinical studies; no peer-reviewed human clinical trials with defined sample sizes, randomization, or quantified effect sizes have been published as of current data. In vitro antimicrobial work documents MICs of 12.5–50.0 µg/ml against 15 H. pylori strains and 62.5 µg/ml against select gram-positive bacteria, and antiproliferative studies demonstrate inhibition of K562 leukemia cell growth correlated with sanguinarine and chelerythrine content, though quantitative IC50 values were not uniformly reported across sources. Immunological studies using human PBMCs show augmentation of proliferation and IFN-γ secretion with flower and root extracts, with correlations between alkaloid concentration and immune response that were described as inconsistent across extract types. Cytotoxicity profiling on intestinal epithelial IPEC-J2 cells represents a first-in-class preclinical safety characterization, but the complete absence of Phase I or Phase II human trials means no clinically actionable efficacy or dosing conclusions can be drawn.
Preparation & Dosage
Traditional preparation
**Ethanol Tincture (Rhizome)**
Most concentrated source of sanguinarine and chelerythrine; traditional preparations use 1:5 rhizome-to-ethanol ratio, but no evidence-based dose range is established for human use.
**Hot Water Infusion**
Yields lower alkaloid concentrations than ethanol extracts; historically used for respiratory complaints, but cold water extracts yield the least alkaloids of all preparation methods.
**Dried Rhizome Powder**
3 g), but standardized extract percentages for commercial products are not established by regulatory agencies
Historically used in small quantities (estimated traditional doses of 0.06–0..
**Topical Preparations**
Applied externally in traditional escharotic formulations; commercial skin products citing bloodroot lack standardized sanguinarine concentrations or evidence-based dosing protocols.
**Timing Note**
Rhizomes harvested mid-spring during flowering contain peak alkaloid concentrations; dormant-season material and leaf/flower fractions contain significantly lower bioactive levels.
**Standardization**
No pharmacopoeial or clinical-trial-validated standardization percentage exists; sanguinarine content should be the reference marker given it comprises up to 50% of total alkaloids and drives primary bioactivity.
Nutritional Profile
Bloodroot rhizomes are not consumed as a food and do not contribute meaningfully to macronutrient or micronutrient intake. Their pharmacological relevance derives entirely from a complex alkaloid profile: sanguinarine (~559.64 mg per 100 g fresh rhizome, approximately 0.55% fresh weight), chelerythrine (second most abundant QBA, highest in ethanol extracts), chelilutine, sanguilutine, sanguirubine, chelirubine, protopine, and allocryptopine, plus berberine (least abundant, highest in flower and root alcohol extracts). Geographic population variation is substantial, with some wild populations yielding up to 9% sanguinarine or 18.7 mg/g chelirubine, making standardization of any preparation highly challenging. Endotoxin content (up to 440 EU/ml in root extracts) represents an additional bioactive constituent not attributable to the alkaloid fraction.
How It Works
Mechanism of Action
Sanguinarine, the dominant alkaloid comprising approximately 44.8–50% of total alkaloids in bloodroot rhizomes, intercalates into double-stranded DNA and inhibits topoisomerase activity, disrupting nucleic acid replication in both microbial and mammalian cancer cells. At the immune level, sanguinarine and chelerythrine modulate cytokine networks by augmenting IFN-γ, IL-2, and TNF-α production while suppressing the anti-inflammatory cytokines IL-4 and IL-10, thereby promoting CD8+ T-cell cytotoxic activity and Th1 polarization. These alkaloids also directly inhibit neutrophil function—blocking chemotaxis, oxidative metabolism, and degranulation—via interference with NADPH oxidase activity and intracellular signaling cascades at concentrations of 0.001%. Additionally, high endotoxin levels detected in rhizome root extracts (up to 440 EU/ml) may contribute independently to innate immune activation, complicating attribution of bioactivity solely to alkaloid fractions.
Clinical Evidence
No controlled human clinical trials investigating bloodroot or its isolated alkaloids for any therapeutic indication have been identified in the peer-reviewed literature. Available preclinical data consist of cell-line antiproliferation assays, bacterial MIC determinations, and human PBMC immunostimulation experiments conducted in vitro without in vivo human validation. The absence of pharmacokinetic data in humans means bioavailability, therapeutic plasma concentrations, and safe exposure durations remain entirely undefined. Confidence in any clinical benefit claim for bloodroot is therefore very low, and all reported activities should be interpreted as hypothesis-generating preclinical observations rather than established therapeutic effects.
Safety & Interactions
Bloodroot is associated with significant toxicity risks; sanguinarine at elevated doses disrupts neutrophil chemotaxis, oxidative metabolism, and degranulation, potentially impairing host defense against bacterial infection, and systemic exposure to high alkaloid doses can cause nausea, vomiting, and mucous membrane irritation. High endotoxin levels in rhizome extracts (up to 440 EU/ml) may independently trigger pyrogenic or inflammatory responses, and the wide natural variability in alkaloid concentrations across geographic populations makes predictable dosing and toxicity thresholds impossible to define without batch-specific standardization. The anti-platelet activity of sanguinarine warrants caution in patients taking anticoagulants (warfarin, heparin), antiplatelet agents (aspirin, clopidogrel), or NSAIDs, though formal pharmacokinetic drug interaction studies have not been conducted. Bloodroot is contraindicated in pregnancy and lactation given emetic and potentially abortifacient properties documented in traditional sources, and topical 'black salve' preparations containing bloodroot carry a documented risk of permanent scarring and disfigurement and should not be used for any skin condition including malignancy.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Sanguinaria canadensisRed PuccoonTetterwortCoon RootIndian PaintPauson
Frequently Asked Questions
Is bloodroot safe to take as a supplement?
Bloodroot is not considered safe for unsupervised supplemental use; its primary alkaloid sanguinarine inhibits neutrophil function at very low concentrations and can cause nausea, vomiting, and mucous membrane damage at higher doses. Topical preparations marketed as skin cancer treatments have caused severe and permanent tissue disfigurement, and no standardized safe dose has been established in human clinical trials. It is contraindicated in pregnancy, lactation, and for individuals on anticoagulant or antiplatelet medications.
What is sanguinarine and what does it do?
Sanguinarine is a quaternary benzophenanthridine alkaloid comprising approximately 44–50% of total alkaloids in bloodroot rhizomes, reaching concentrations of up to 559 mg per 100 g fresh plant material. It exerts antimicrobial effects (MIC 12.5–50 µg/ml against H. pylori), inhibits DNA topoisomerase and intercalates double-stranded DNA in cancer cell lines, and modulates immune cytokines by upregulating IFN-γ and TNF-α while suppressing IL-4 and IL-10. All demonstrated effects are currently limited to in vitro and preclinical research with no confirmed human clinical data.
Can bloodroot cure or treat skin cancer?
There is no clinical evidence that bloodroot or any bloodroot-containing preparation (including 'black salve') can treat or cure skin cancer; this claim is unsupported by peer-reviewed clinical trials and has been flagged as dangerous by regulatory agencies. Topical application of escharotic bloodroot preparations has been documented to cause permanent scarring, deep tissue destruction, and disfigurement without reliably eliminating malignant cells. Individuals with suspected skin cancer should consult a board-certified dermatologist for evidence-based diagnosis and treatment.
How was bloodroot traditionally used by Native Americans?
Native American nations including the Algonquin, Cherokee, and Iroquois used bloodroot rhizome preparations topically as an antimicrobial escharotic agent for skin infections and growths, inhaled its powdered root for nasal polyps and respiratory congestion, and applied its red sap as ceremonial body and face paint. Internal preparations were used in small doses for respiratory ailments including bronchitis and croup, and Eclectic physicians later formalized these uses in 19th-century American materia medica. Rhizomes were typically harvested in mid-spring during peak flowering to maximize alkaloid content.
What is the difference between sanguinarine and chelerythrine in bloodroot?
Both sanguinarine and chelerythrine are quaternary benzophenanthridine alkaloids found in bloodroot rhizomes, but sanguinarine is consistently the most abundant, comprising up to 50% of total alkaloids, while chelerythrine is the second most concentrated and reaches its highest levels in ethanol rhizome extracts. Sanguinarine is primarily responsible for antimicrobial, anti-inflammatory, and antiproliferative activities documented in vitro, while chelerythrine also contributes to antiproliferative effects as evidenced by its correlation with K562 cell growth inhibition in extract studies. Both alkaloids carry cytotoxicity risks, and their relative concentrations vary significantly across geographic populations and seasonal harvest timing.
What does research show about bloodroot's antimicrobial effectiveness?
In vitro studies demonstrate that sanguinarine and chelerythrine in bloodroot exhibit broad-spectrum antimicrobial activity with minimum inhibitory concentrations (MICs) of 12.5–62.5 µg/ml against pathogens including H. pylori and E. coli, supporting historical antimicrobial applications. However, these laboratory results have not been conclusively replicated in human clinical trials, meaning efficacy in the body remains unproven. The gap between in vitro potency and real-world human effectiveness is a key limitation in evaluating bloodroot's antimicrobial potential.
Are there specific groups who should avoid taking bloodroot supplements?
Bloodroot should be avoided by pregnant and nursing women due to the potential toxicity of alkaloids like sanguinarine, which may cross the placenta and enter breast milk. Individuals with a history of skin sensitivity, dermatological conditions, or those taking immunosuppressive medications should consult a healthcare provider before use. People with gastrointestinal conditions should exercise caution, as internal bloodroot use carries higher risk of serious adverse effects compared to topical application.
How does the bioavailability of bloodroot differ between topical and oral supplementation?
Topical bloodroot preparations deliver alkaloids directly to skin tissue, achieving localized antimicrobial and antiproliferative effects with minimal systemic absorption, which is why historical and traditional applications focused on external use. Oral supplementation of bloodroot requires the alkaloids to survive gastric acid and intestinal metabolism before systemic absorption, significantly reducing bioavailability and increasing risk of systemic toxicity. This fundamental difference in delivery explains why topical bloodroot formulations are generally considered safer than oral supplements, despite limited clinical evidence supporting either route.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w bloodroot-sanguinaria-canadensis curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
